June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Prosthetic Replacement of the Ocular Surface Ecosystem (PROSE) Treatment: A Partner Clinic Experience
Author Affiliations & Notes
  • Kira Segal
    Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
  • Michelle Lee
    Ophthalmology, NewYork-Presbyterian, New York, NY
  • Kristin Chapman
    Ophthalmology, NewYork-Presbyterian, New York, NY
  • Mark Rosenblatt
    Ophthalmology, NewYork-Presbyterian, New York, NY
  • Kimberly Sippel
    Ophthalmology, NewYork-Presbyterian, New York, NY
  • Christopher Starr
    Ophthalmology, NewYork-Presbyterian, New York, NY
  • Jessica Ciralsky
    Ophthalmology, NewYork-Presbyterian, New York, NY
  • Footnotes
    Commercial Relationships Kira Segal, None; Michelle Lee, None; Kristin Chapman, None; Mark Rosenblatt, None; Kimberly Sippel, None; Christopher Starr, None; Jessica Ciralsky, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 5485. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kira Segal, Michelle Lee, Kristin Chapman, Mark Rosenblatt, Kimberly Sippel, Christopher Starr, Jessica Ciralsky, ; Prosthetic Replacement of the Ocular Surface Ecosystem (PROSE) Treatment: A Partner Clinic Experience. Invest. Ophthalmol. Vis. Sci. 2013;54(15):5485.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

PURPOSE: To evaluate demographics, clinical course, and outcomes of patients who received the PROSE device at a partner clinic.

 
Methods
 

METHODS: Retrospective chart review of 37 consecutive patients (66 eyes) fit with the PROSE device.

 
Results
 

RESULTS: Indications for PROSE treatment included ectasia in 17 eyes (25.8%) and ocular surface disease in 49 eyes (74.2%). The average follow-up time was 4.76 months (2.4-9.35). Visual acuity improved with the PROSE device a statistically significant amount (p=0.002). All patients had improved ocular symptoms and decreased reliance on topical lubricants.

 
Conclusions
 

CONCLUSIONS: PROSE is an effective treatment option for many patients with complex corneal diseases.

 
Keywords: 477 contact lens • 486 cornea: tears/tear film/dry eye • 574 keratoconus  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×